AR060065A1 - Formas cristalinas de un compuesto - Google Patents

Formas cristalinas de un compuesto

Info

Publication number
AR060065A1
AR060065A1 ARP070101183A ARP070101183A AR060065A1 AR 060065 A1 AR060065 A1 AR 060065A1 AR P070101183 A ARP070101183 A AR P070101183A AR P070101183 A ARP070101183 A AR P070101183A AR 060065 A1 AR060065 A1 AR 060065A1
Authority
AR
Argentina
Prior art keywords
salt
acid
compound
crystal forms
difluorocyclohexyl
Prior art date
Application number
ARP070101183A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR060065A1 publication Critical patent/AR060065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se describe una sal del compuesto N-{2-terc-butil-1-[(4,4-difluorciclohexil)metil]-1H-benzimidazol-5-il}etansulfonamida, que es una sal dle ácido etansulfonico, una sal del ácido sulfurico, una sal del ácido etandisulfonico, una sal del ácido clorhídrico, una sal del ácido bromhídrico, una sal del ácido fosforico, una sal del ácido acético, una sal del ácido fumárico, una sal del ácido maleico, una sal del ácido tartárico, una sal del ácido cítrico, una sal del ácido metansulfonico o una sal del ácido p-toluensulfonico de dicho compuesto.
ARP070101183A 2006-03-23 2007-03-22 Formas cristalinas de un compuesto AR060065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78532606P 2006-03-23 2006-03-23

Publications (1)

Publication Number Publication Date
AR060065A1 true AR060065A1 (es) 2008-05-21

Family

ID=38522716

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101183A AR060065A1 (es) 2006-03-23 2007-03-22 Formas cristalinas de un compuesto

Country Status (18)

Country Link
US (2) US7566788B2 (es)
EP (1) EP2001856A4 (es)
JP (1) JP2009530373A (es)
KR (1) KR20080105098A (es)
CN (1) CN101454293A (es)
AR (1) AR060065A1 (es)
AU (1) AU2007227811A1 (es)
BR (1) BRPI0709631A2 (es)
CA (1) CA2648829A1 (es)
EC (1) ECSP088714A (es)
IL (1) IL193671A0 (es)
MX (1) MX2008012015A (es)
NO (1) NO20084353L (es)
RU (1) RU2008136556A (es)
TW (1) TW200745049A (es)
UY (1) UY30232A1 (es)
WO (1) WO2007108754A1 (es)
ZA (1) ZA200807598B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
CN101758337B (zh) 2009-12-03 2012-02-15 湖南阿斯达生化科技有限公司 一种助焊剂用非卤素活性剂
GB202019335D0 (en) * 2020-12-09 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (es) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
WO2001012600A1 (en) 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
RU2002110295A (ru) 1999-09-17 2003-12-10 Милленниум Фармасьютикалс, Инк. (Us) Ингибиторы фактора Ха
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
EE05515B1 (et) 2000-01-14 2012-02-15 Schering@Aktiengesellschaft 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
AU2002221239A1 (en) 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005007625A2 (en) 2003-07-14 2005-01-27 The University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20060035884A1 (en) 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006009876A2 (en) 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
PT1773768T (pt) 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
US20060052421A1 (en) 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
JP2008514595A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それを含有する組成物、その製造及びその使用ｉｉ
WO2006033628A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006033627A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iiii
AU2005287426A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof III
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
JP2008514594A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用ｉ
CA2581232C (en) * 2004-09-24 2015-04-07 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
EP1797075A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands
DE602005011844D1 (de) 2004-11-02 2009-01-29 Pfizer Sulfonylbenzimidazolderivate
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof

Also Published As

Publication number Publication date
WO2007108754A1 (en) 2007-09-27
MX2008012015A (es) 2008-10-01
US7566788B2 (en) 2009-07-28
UY30232A1 (es) 2007-10-31
EP2001856A4 (en) 2011-02-16
TW200745049A (en) 2007-12-16
AU2007227811A1 (en) 2007-09-27
CN101454293A (zh) 2009-06-10
US20100022610A1 (en) 2010-01-28
KR20080105098A (ko) 2008-12-03
BRPI0709631A2 (pt) 2011-07-19
CA2648829A1 (en) 2007-09-27
EP2001856A1 (en) 2008-12-17
US20070225346A1 (en) 2007-09-27
NO20084353L (no) 2008-10-16
JP2009530373A (ja) 2009-08-27
ECSP088714A (es) 2008-10-31
IL193671A0 (en) 2009-05-04
RU2008136556A (ru) 2010-04-27
ZA200807598B (en) 2010-02-24

Similar Documents

Publication Publication Date Title
AR060065A1 (es) Formas cristalinas de un compuesto
CR9755A (es) Derivados de 1-h-pirrol sustituidos con 1-heterocíclilsulfonilo, 2aminoetilo, 5-(hetero-) arilo como inhibidores de la secreción de ácido
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
NO20081476L (no) Substituerte benzimidazoler og fremgangsmater for fremstilling
CR20110369A (es) Derivados de quinazolinona útiles como antagonistas de vanilloides
EA200800549A1 (ru) Региоселективный способ получения бензимидазолтиофенов
DOP2006000234A (es) Inhibidores de cinasa
BR112012008020B8 (pt) máquina de perfuração.
CY1117860T1 (el) Διαβλεννογονια χορηγηση 2-(10-υδροξυδεκυλ)-5,6-διμεθοξυ-3-μεθυλ-2,5-κυκλοεξαδιενο-1,4-διονης (ιδεβενονη)
EA200801592A1 (ru) Макроциклические ингибиторы фактора viia и их применение в качестве антикоагулянтов
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
ATE536127T1 (de) Mehrseitiger waschlappen
ES2421896T3 (es) Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C
DOP2006000233A (es) Inhibidores de cinasa
WO2011021214A3 (en) Improved process for preparing (s)-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)benzothiazole and its dhtydrochloride monohydrate
DE112007003237A5 (de) Nachspannendes Bohrfutter
DE502005007950D1 (de) Brause
UY31704A (es) Compuesto heterociclico fusionado
UY30577A1 (es) Derivados de éter diarilico y usos de los mismos
DK1718337T3 (da) Nye kombinationer af en 5-HT3 receptorantagonist med racecadotril eller dexecadotril
AR063646A1 (es) Proceso para la sulfinilacion de un derivado de pirazol
IT1392392B1 (it) Processo per la purificazione di una corrente acquosa proveniente dalla reazione di fischer-tropsch
EA201001889A1 (ru) Производные дибензотиазепина и их применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure